Home/Investors/Syncona

Syncona

Biotech Investor · 7 portfolio companies

Portfolio

7

Combined Value

$411.2M

Focus Areas

10

Top Stage

phase-2

Investment Focus

Oncology Autoimmune Diseases Cardiovascular Hematology Hematological Oncology Immunology CNS Rare Disease Nephrology Ophthalmology

Portfolio Companies

Company	Stage	Valuation	Focus
Autolus Therapeutics	Phase 2/Pivotal	$411.2M	Oncology, Autoimmune Diseases
ClotProtect	phase-2	—	Cardiovascular, Hematology
Yellowstone Biosciences	Pre-clinical	—	Oncology, Hematological Oncology
Kesmalea Therapeutics	Pre-clinical	—	Oncology, Immunology
Purespring Therapeutics	preclinical	—	Rare Disease, Nephrology
Beacon Therapeutics	phase-2	—	Ophthalmology, Rare Disease
SignaCor	phase-2	—	Oncology

Frequent Co-Investors

Cambridge Innovation Capital2 shared JJDC1 shared RTW Investments1 shared IP Group1 shared Oxford Science Enterprise1 shared UCL Technology Fund1 shared